Literature DB >> 10912621

Cytokine-producing T cell subsets in human leishmaniasis.

K Kemp1.   

Abstract

Leishmania specific Th1/Th2 cells have been identified in humans as well as in mice. There is a correlation between the clinical outcome of the infection and the cytokine response profile. Generally, the production of Th2 cytokines leads to severe infection, whereas the production of Th1 cytokines leads to subclinical or mild infections. In mice, an infection leads to a polarisation of either Th1 or Th2 Leishmania antigen specific cells. In contrast, both Th1 and Th2 Leishmania antigen specific cells can be identified in humans cured from L. donovani infections. Theoretically, Th1 cells and Th2 cells mutually down-regulate each other. However, the presence of antigen specific regulatory T cell subsets may provide an environment that allows the presence of both Th1 and Th2 cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912621

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  14 in total

1.  Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination.

Authors:  Barbara Papadopoulou; Gaétan Roy; Marie Breton; Christoph Kündig; Carole Dumas; Isabelle Fillion; Ajay K Singh; Martin Olivier; Marc Ouellette
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.

Authors:  P Khare; A K Jaiswal; C D P Tripathi; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2016-04-27       Impact factor: 4.330

3.  Histopathological outcome of Leishmania major-infected BALB/c mice is improved by oral treatment with N-acetyl-l-cysteine.

Authors:  Etel Rocha-Vieira; Ellen Ferreira; Priscila Vianna; Daniela R De Faria; Soraya T Gaze; Walderez O Dutra; Kenneth J Gollob
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

Review 4.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 5.  Present status of antileishmanial vaccines.

Authors:  Monidipa Ghosh; Santu Bandyopadhyay
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

6.  Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis.

Authors:  Pramod Kumar Kushawaha; Reema Gupta; Chandra Dev Pati Tripathi; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

7.  Leishmania infantum leishmaniasis in corticosteroid--treated patients.

Authors:  Silvia Pittalis; Emanuele Nicastri; Francesco Spinazzola; Piero Ghirga; Michele De Marco; Maria Grazia Paglia; Pasquale Narciso
Journal:  BMC Infect Dis       Date:  2006-12-18       Impact factor: 3.090

8.  Efficacy of Recombinant Canine Distemper Virus Expressing Leishmania Antigen against Leishmania Challenge in Dogs.

Authors:  Ryuichi Miura; Takanori Kooriyama; Misako Yoneda; Akiko Takenaka; Miho Doki; Yasuyuki Goto; Chizu Sanjoba; Yasuyuki Endo; Tomoko Fujiyuki; Akihiro Sugai; Kyoko Tsukiyama-Kohara; Yoshitsugu Matsumoto; Hiroki Sato; Chieko Kai
Journal:  PLoS Negl Trop Dis       Date:  2015-07-10

Review 9.  Pleiotropic Effect of Hormone Insulin-Like Growth Factor-I in Immune Response and Pathogenesis in Leishmaniases.

Authors:  Luiza C Reis; Eduardo Milton Ramos-Sanchez; Fernanda N Araujo; Ariane F Leal; Christiane Y Ozaki; Orlando R Sevillano; Bernardina A Uscata; Hiro Goto
Journal:  J Immunol Res       Date:  2021-05-04       Impact factor: 4.818

10.  T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?

Authors:  James Alexander; Frank Brombacher
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.